Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in the next generation of precision cardiovascular medicine technologies that combine proprietary AI algorithms with epigenetic and genetic ...

Allowing physicians to choose a cardiac stress imaging modality for patients with lower-risk chest pain can save more than $300 compared to mandating a cardiac magnetic resonance test, according to a ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...

Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS) The final gapfill payment rate for both the Epi+Gen ...